Research graph
References from Presentation and management of tislelizumab induced toxic optic neuropathy. Local targets link to admitted publications; unresolved targets remain external evidence.
Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer
10.4103/apjon.apjon_4_17 · 2017 · External reference
Ocular adverse events associated with immune checkpoint inhibitors, a scoping review
10.1186/s12348-022-00321-2 · 2023 · External reference
Ocular adverse events in PD-1 and PD-L1 inhibitors
10.1136/jitc-2020-002119 · 2021 · External reference
10.1016/j.ajo.2019.02.012
10.1016/j.ajo.2019.02.012 · External reference
Reactive Astrocytes in Glioma: Emerging Opportunities and Challenges
10.3390/ijms26072907 · 2025 · External reference
Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: Current status and future directions
10.3389/fopht.2022.1044904 · 2022 · External reference
Ophthalmic Immune-Related Adverse Events and Association with Survival: Results From a Real-World Database
10.1016/j.ajo.2024.08.044 · 2024 · External reference
P06.17.A optic neuropathy related to immune checkpoint inhibitors: A case series
10.1093/neuonc/noad137.157 · 2023 · External reference
Immune Checkpoint Inhibitor-Associated Optic Neuritis
10.1016/j.ophtha.2020.05.003 · 2020 · External reference
10.3389/fphar.2025.1678663
10.3389/fphar.2025.1678663 · External reference
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
10.1016/j.jtho.2024.03.008 · 2024 · External reference
10.1097/icb.0000000000001817
10.1097/icb.0000000000001817 · External reference
Tislelizumab-induced Vogt-Koyanagi-Harada-like uveitis: a case report
10.1186/s12886-026-04743-7 · 2026 · External reference
Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm
10.1177/1758835921992989 · 2021 · External reference
Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors
10.1136/jitc-2024-011049 · 2025 · External reference
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
10.1136/jitc-2021-002435 · 2021 · External reference
10.1200/jco.21.01440
10.1200/jco.21.01440 · External reference
